The world's largest maker of cancer drugs said sales rose 5 percent to 11.78 billion Swiss francs ($12.5 billion), slightly ahead of the average forecast of 11.57 billion in a Reuters poll.
Roche confirmed its guidance for low-to-mid single digit sales growth this year at constant exchange rates and its target for core earnings per share (EPS) to grow ahead of sales.
It expects to increase its dividend from the 7.80 Swiss francs per share it paid out in 2013.